INTRODUCTION
============

Lithium salts are used in the treatment of mania and as prophylaxis against manic depressive disorder ([@b3]). Lithium is normally present in the body at trace concentrations and is toxic at higher concentrations. In therapeutic treatment, it is dosed in concentrations below 2 mM ([@b13]). A long period of treatment with lithium causes lesions to the gastroenteric tube, the nervous system, and kidneys. The therapeutic activity of lithium is supposed to be caused by lithium inhibition of inositol phosphatases, especially the inositol monophosphatase ([@b7]). Lithium also reduces brain concentrations of prostaglandin E~2~ and cyclogenase 2 ([@b12]), as well as decreases phospholipase A~2~ activity ([@b12]; [@b2]). Most investigations concerning the lithium effect explain its therapeutic effect. However, the high ability of lithium to inhibit numerous enzymes may also be a reason for unexpected side effects.

EXPERIMENTAL
============

HPLC analysis was done with a Merck Hitachi liquid chromatograph with a diode array detector (model L-4500, Tokyo Japan). A Superspher Si 60 column (250 x 4 mm) was applied. Phospholipids standards-phosphatidylinositol (porcine liver), phosphatidylserine (bovine brain), phosphatidylethanolamine (porcine liver), and phosphatidylcholine (porcine liver) (Larodan AB, Sweden) were used. Butylated hydroxytoluene (BHT) (analytical grade Sigma-Aldrich) as well as sodium phosphate buffer-1 (osmolality 310 mmol/kg^−1^, pH = 7.4) and sodium phosphate buffer-2 (osmolality 20 mmol/kg^−1^ pH = 7.4), acetonitrile, methanol, n-hexane, and isopropanol (all gradient grade for chromatography, Merck) were used. Other reagents including lithium carbonate were of analytical grade. Water was deionized with a MiliQ(Milipore) apparatus. All solvents in the experiment were deoxidized with a Polsonic ultrasonic cleaner.

Blood samples taken from eight different healthy adult subjects were supplied by the Blood Donor Centre of Bialystok. The age of the donors varied between 20 and 50 years. Blood was treated with EDTA as an anticoagulant. The procedural sequence of isolation of erythrocyte membranes and extraction of phospholipids was performed in accordance to [@b11] and [@b9] and is given in [Figure 1](#fig1){ref-type="fig"}. The erythrocytes were incubated at 37°C for 1 h with 10 mM lithium carbonate in the phosphate buffer-1. To prevent the oxidation of phospholipids during extraction, 0.03% of BHT was added, along with flushing with nitrogen at each step of the procedure. Separation and determination of isolated phospholipids were performed by normal phase HPLC with iso-cratic elution. The mobile phase was acetonitrile-methanol-85% phosphoric acid mixture of 130:5:1.5 volume ratio. The flow rate of the mobile phase was 1 mL/min^−1^. The chromatogram was recorded at 214 nm wavelength ([@b9]). The peaks of phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC) are well separated. Unfortunately, sphingomyelin is not determined under the selected conditions.

![Isolation of erythrocyte membranes and phospholipid extraction.](utxm18-515-f1){#fig1}

Statistical Analysis
--------------------

The results are expressed as mean values ± SD (n = 8). Statistically significant differences were determined by the Student\'s *t*-test, as well as ANOVA. *p* ≤ 0.05 was considered statistically significant.

RESULTS AND DISCUSSION
======================

These studies investigate the effect of lithium on phospholipids of human erythrocyte membranes. Concentrations of lithium above the therapeutic dose by half an order of magnitude and in vitro experiments were undertaken. Results are shown in [Figure 2](#fig2){ref-type="fig"}. The results clearly indicate the statistically significant decrease in PC content in erythrocytes due to lithium in vitro treatment. This effect was predicted by [@b5] and [@b4], but not observed in in vivo experiments with persons treated with lithium ([@b10]; [@b1]). [@b5] and simultaneously [@b4] discovered 10 to 30 times higher choline levels in erythrocytes treated with lithium and predicted that choline originates from a breakdown of phosphatidylcholine. The reason for the difference between in vitro and in vivo experiments is probably significantly lower lithium concentrations in the in vivo experiments and complex reactions involving lithium.

![Comparison of the phospholipid content of erythrocyte membranes as a percentage of the total phospholipids from Li^+^-treated and Li^+^-untreated (control). \* Statistically significant differences for p ≤ 0.05 with respect to control.](utxm18-515-f2){#fig2}

The other result of the research is an increase in PI content. Although it is a surprising effect, the increase is statistically significant. A similar effect is observed in neuroblastoma membranes during chronic Li^+^ treatment for 4 to 6 weeks ([@b6]). This may be caused by the inhibition of PI phosphorylation to PIP (phosphatidylinositol-4-phosphate) and subsequently to PIP2 (phosphatidylinositol-4,5-bisphosphate), which is the next stage in the PI cycle ([@b14]). This is why PI is accumulated in membranes, since the synthesis of PI is not inhibited but PI transformation is stopped. Probably the inositol accumulation process could be connected with the phosphatidilcholine decrease. Phos-phatidilcholine undergoes hydrolysis into phosphatidic acid and free choline. Then phosphatidic acid changes into the form of diacylglicerol (DAG). DAG is converted into cytidine diphosphate-diacylglycerol (CDP-DAG). CD-DAG could react with inositol to form phosphatidylinositol (PI) ([@b14]; [@b8]).
